Slide background

Slide background
Slide background
Slide background

Loading Events
September
2017
21
JLABS @ NYC: Sell Your Science

11:00 AM — 1:00 PM

Best Practices for Developing an Effective Non-Confidential Pitch Deck

See New York Genome Center’s lecture series, events and archives VIEW FULL CALENDAR

About

 

 

Best Practices for Developing an Effective Non-Confidential Pitch Deck

 

 

Join us for a session on learning the tricks of the trade in preparing a non-confidential deck and executive summary. Experts of the craft will share practical tips on becoming more effective in communicating your story to Angel investors and venture capitalists, increasing your chances of successful fundraising.

 

Agenda:

 

11:00 AM | Registration Opens
11:15 AM | Networking Lunch*
12:00 PM | Presentation
12:45 PM | Q&A
1:00 PM | Program Close
*Light food & beverage provided

 

Register

 

Location:

 

New York Genome Center
101 6th Ave, 1st floor
New York, NY 10013

 

 

 

Speaker:

 

Tom Luby, PhD | Head of JLABS, Texas, Johnson & Johnson Innovation

 

Dr. Luby is the new Head of JLABS in Texas. Previously, he was the Senior Director of New Ventures at Johnson & Johnson Innovation in Boston where he focused primarily on cardiovascular, metabolism, infectious diseases, vaccines and neurobiology. Prior to joining the Johnson & Johnson Family of Companies, Dr. Luby was the Senior Director of Research Ventures at Shire Human Genetic Therapies. In this position, he played a central role in the evaluation, diligence, and deal processes across a number of successful early-stage investments in the rare disease space. He was member of the Board of Directors at ArmaGen Technologies, led the collaboration with Nimbus Discovery, and was instrumental in establishing and leading the alliance that Shire put in place with Atlas Venture. Prior to working with Nimbus, Dr. Luby held a variety of research and development roles in both start-up and mid-sized biotech companies. He has worked on multiple discoveries through Phase II programs in infectious diseases, oncology, immunotherapy and monogenetic disorders. His experience includes pre-clinical development, early-stage portfolio oversight, licensing, due diligence, company formation, alliance management and key opinion leader outreach.

Dr. Luby received his BSc. in Biology from State University of New York, his PhD in Immunology from Tufts University, and was a Postdoctoral Fellow in Yeast Genetics at Harvard School of Public Health.

  • +
    EVENING TALKS
    • +
      VIDEO ARCHIVE